The independent source for health policy research, polling, and news.
1-20 of 243 results
The rapid emergence of the Chinese biotech industry has panicked U.S. politicians, but investors and patients caution that a clampdown on pharmaceutical collaboration could hurt everyone.
KFF Health News gives readers a chance to comment on a recent batch of stories.
A doctor has recommended a course of action that is invasive, expensive, or somehow different from what you'd prefer. Is it OK to get a second opinion? The answer is yes. Here’s how to make the ask a little less awkward.
Tests like full-body scans marketed directly to consumers are pitched as a way to detect diseases early and establish a baseline of health markers. But there are financial, physical, and psychological risks to all medical tests — and in some cases, not getting a test could be better for your health.
President Donald Trump has championed sprawling health policy changes under the Make America Healthy Again movement, but a KFF-Associated Press survey of rural voters found people aren’t seeing the initiatives reach their communities.
“Brain cancer” or “H4 G34-mutant”? As knowledge about genetics advances, some doctors say cancers should be defined by their mutations, not the tissues where they manifest.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
As state governments grapple with how to determine who’s sick enough to be excused from new Medicaid work requirements, some families are already struggling with what illnesses guarantee health coverage because of a disability.
Stephanie Halver’s doctor recommended she get a breast MRI, partly because of her family’s cancer history. Her insurer approved the scan, but unlike mammograms, breast MRIs aren’t universally covered as zero-cost preventive care.
Patients and researchers point to evidence that many cancer drug dosages are excessive, and that reducing the amount and frequency could save billions of dollars and prevent some of the worst side effects.
The Department of Health and Human Services has launched an effort to streamline clinical research, and legislation is pending in Congress. But patients and providers face participation challenges.
Lung cancer remains the leading cause of cancer deaths in the United States, and older adults are at higher risk. But only about a quarter of patients eligible for screening are up to date.
Amid advancements in treatment and screening, more Americans are surviving the disease. But many are left with psychological scars, such as lingering anxiety and depression.
In the U.S., more than a dozen kinds of cancer are on the rise among people under 50. The HealthQ team shares the latest guidance on being proactive with your family and doctor.
The FDA has approved the sunscreen chemical bemotrizinol, a UV light filter that has been available in Europe, Asia, and Australia for more than 20 years. Health advocates and skin care industry groups alike are hopeful it can restore faith in sunscreen.
KFF Health News' editor-at-large for public health discussed Ebola, GLP-1 drugs, ultraprocessed food, and more in TV appearances this week.
KFF Health News' editor-at-large for public health discussed peptides, colorectal cancer screening, and Ebola in TV appearances this week.
A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
© 2026 KFF